ADVM:NSD-Adverum Biotechnologies Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.23

Change

-0.05 (-2.19)%

Market Cap

USD 0.22B

Volume

0.89M

Avg Analyst Target

USD 5.63 (+152.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A

ETFs Containing ADVM

Symbol Name Weight Mer Price(Change) Market Cap
DRUP:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

-0.04 (-0.24%)

USD0.34B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -79.43% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.43% 1% F 1% F
Trailing 12 Months  
Capital Gain -79.37% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.37% 1% F 1% F
Trailing 5 Years  
Capital Gain -46.90% 39% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.90% 39% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 55.34% 77% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.34% 77% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 86.30% 35% F 20% F
Risk Adjusted Return 64.13% 89% B+ 79% C+
Market Capitalization 0.22B 39% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.60 99% A+ 97% A+
Price / Cash Flow Ratio -2.82 23% F 59% F
EV/EBITDA 0.06 83% B 97% A+
Management Effectiveness  
Return on Equity -41.76% 67% D+ 32% F
Return on Invested Capital -39.07% 61% D- 21% F
Return on Assets -20.06% 63% D 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.32 24% F 13% F
Short Percent 16.25% 7% F 9% F
Beta 1.13 62% D- 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector